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High-density lipoprotein (HDL) possesses multiple biological activities; small, dense 
HDL3c particles displaying distinct lipidomic composition exert potent antiatherogenic 
activities which can be compromised in dyslipidemic, hyperglycemic insulin-resistant states. 
However, it remains indeterminate (i) whether such functional HDL deficiency is related to 
altered HDL composition, and (ii) whether it originates from atherogenic dyslpidemia, 
dysglycemia, or both.  
In the present work we analysed compositional characteristics of HDL subpopulations 
and functional activity of small, dense HDL3c particles in treatment-naïve patients with well-
controlled (n=10) and poorly-controlled (n=8) Type 2 diabetes (T2D) and in normolipidemic 
age- and sex-matched controls (n=11).  
Our data reveal that patients with both well- and poorly-controlled T2D displayed 
dyslipidemia and low-grade inflammation associated with altered HDL composition. Such 
compositional alterations in small, dense HDL subfractions were specifically correlated with 
plasma HbA1c levels. Further analysis using a lipidomic approach revealed that small, dense 
HDL3c particles from T2D patients with poor glycemic control displayed additional 
modifications of their chemical composition. In parallel, antioxidative activity of HDL3c 
towards oxidation of low-density lipoprotein was diminished.  
These findings indicate that defective functionality of small, dense HDL particles in 
patients with T2D is not only affected by the presence of atherogenic dyslipidemia, but also 
by the level of glycemic control, reflecting compositional alterations of HDL. 
 


















ANOVA: Analysis of Variance 
ApoAI: Apolipoprotein AI 
ApoB: Apolipoprotein B 
BMI: Body Mass Index 
CVD: Cardiovascular Disease 
CE: Cholesteryl Ester 
CETP: Cholesteryl Ester Transfer Protein 
EDTA: Ethylene Diamine Tetra acetic acid 
EGF: Endothelial Growth Factor 
FC: Free Cholesterol 
GP: Generalized Polarization 
HbA1c: Glycated Hemoglobin 
HDL: High-Density Lipoprotein 
HDL-C: HDL-Cholesterol 
HsCRP: High-Sensitive C-Reactive Protein  
ICAM-1: Intercellular Cell Adhesion Molecule-1 
IDL: Intermediate Density Lipoprotein 
IL-6: Interleukin 6 
LCAT: Lecithin Cholesterol Acyl Transferase 
LDL: Low-Density Lipoprotein 
LDL-C: LDL-Cholesterol 
Lp-PLA2: Lipoprotein-Associated Phospholipase A2  
















PBS: Phosphate-Buffered Saline 
PC: Phosphatidylcholine 
PL: Phospholipids 
PON1: Paraoxonase 1 
SM: Sphingomyelin 
TC: Total Cholesterol 
TG: Triglycerides 
TP: Total Protein 
VEGF: Vascular Endothelial Growth Factor 
VCAM-1: Vascular Cell Adhesion Molecule 1 

















Insulin-resistant states are associated with elevated risk of cardiovascular disease 
(CVD); indeed, Type 2 diabetes (T2D) represented a major CVD risk factor in the 
INTERHEART study across 52 countries worldwide (1). Atherogenic dyslipidemia, involving 
hypertriglyceridemia and low circulating levels of high-density lipoprotein-cholesterol (HDL-
C), is a key component of excess CVD risk in insulin-resistant states, and notably in T2D (2-
4). In addition, diabetic dyslipidemia results in qualitative modifications of HDL particles that 
are thought to diminish their antiatherogenic capacities, which include effluxing cellular 
cholesterol, protecting low-density lipoprotein (LDL) against oxidative stress, diminishing 
cellular death, decreasing vascular constriction, reducing inflammatory response, and 
improving glucose metabolism, among others (5). Importantly, such biological functions 
directly rely on HDL composition and structure, with phospholipids (PLs) being of critical 
importance (6). 
Plasma HDL is markedly heterogeneous in composition, structure, metabolism and 
function, comprising different particles which range from large, cholesteryl ester-rich, 
protein-poor HDL2 to small, dense, protein-rich HDL3 subfractions (7, 8). Our previous 
studies have revealed that HDL3c particles exhibit more potent antiatherogenic properties as 
compared to other HDL subpopulations (7). Indeed, cholesterol efflux capacity, antioxidative 
activity toward LDL oxidation, antithrombotic activity in human platelets, anti-inflammatory 
activity, and antiapoptotic activity in endothelial cells were all enriched in the small, dense, 
protein-rich HDL3c relative to other HDL subfractions (6, 9). Importantly, biological 
activities of small, dense HDL have been reported to be markedly altered in patients with 
insulin resistance and inflammation (10-12). 
However, since the majority of earlier studies do not distinguish between patients with 
















dysglycemia for compositional and functional HDL alterations in T2D still remain 
indeterminate. To provide further insight into this question, we studied compositional and 
functional characteristics of HDL particles in two groups of treatment-naïve patients with 
well- and poorly-controlled T2D and in a group of healthy age- and sex-matched 
normolipemic controls.  
Our data revealed that glycemic status preferentially affected small, dense HDL3c 
particles which displayed distinct compositional alterations closely related to increased 
cholesteryl ester transfer protein (CETP) activity. Moreover, antioxidative activity of small, 
dense HDL3c was specifically reduced in T2D patients with poor glycemic control. 
Lipidomic analyses showed that HDL3c from poorly-controlled patients displayed additional 
alterations that were associated with functional HDL deficiency.  
Taken together, our findings indicate that antioxidative deficiency of small, dense 
HDL particles in patients with T2D is not only affected by the presence of atherogenic 


















2. Materials and Methods 
2.1 Subjects 
Eighteen treatment-naïve adult patients with T2D (males and postmenopausal women) 
diagnosed according to the American Diabetes Association (ADA) criteria (13) were recruited 
from the Ramon Carrillo Centre, La Matanza, Buenos Aires, Argentina. Subjects presenting 
any of the following criteria were excluded: a) history of cardiovascular disease, b) 
concomitant kidney, thyroid or liver disease, c) excessive alcohol consumption, d) smoking, 
and e) treatment with drugs affecting lipid or carbohydrates metabolism and/or with 
antioxidants during the last 6 months. Diabetic patients were in turn divided into 2 groups, 
well- and poorly-controlled, following the ADA glycemic recommendations for patients with 
diabetes (13). Accordingly, poorly-controlled patients were defined as those presenting 
HbA1c > 7% and fasting glucose > 130 mg/dl (T2DPC, n=8), while the remaining 10 diabetic 
patients constituted the well-controlled (T2WC) group. Eleven healthy non-smoking 
normolipidemic subjects were recruited from the same geographical area and with similar 
socio-demographic characteristics to constitute the control group. Written informed consent 
was obtained from all patients and control subjects and the study was approved by the Ethics 
Committee of the Faculty of Pharmacy and Biochemistry, University of Buenos Aires, in 
accordance with guidelines conformed to the Declaration of Helsinki. 
2.2 Blood Samples 
Blood samples were withdrawn from the antecubital vein of each participant after a 12 
h overnight fast. Serum and Na2EDTA plasma (final Na2EDTA concentration, 1 mg/ml) were 
prepared from venous blood collected into sterile, evacuated tubes (Vacutainer). Plasma was 
immediately separated by low-speed centrifugation at 4°C; serum and plasma were each 
















aliquoted and frozen at -80°C under nitrogen. Each aliquot was thawed only once directly 
before analyses.  
2.3 Clinical and Biological Parameters 
Circulating levels of glucose, HbA1c, total cholesterol (TC), triglyceride.s (TG), low-
density lipoprotein-cholesterol (LDL-C) and HDL-C were measured using commercially 
available enzymatic kits (Wiener Lab, Argentina). Non-HDL-C was calculated as a difference 
between TC and HDL-C. Very low-density lipoprotein-cholesterol (VLDL-C) was calculated 
as a difference between TC, LDL-C and HDL-C. Plasma apolipoprotein (apo) A-I and apoB 
were quantitated by immunoturbidimetry (Diasys, France). High-sensitivity C-reactive protein 
(hsCRP) was measured by immunoassay (Roche Diagnostics, Mannheim, Germany). Plasma 
levels of interleukin 6 (IL-6), vascular cell adhesion molecule (VCAM)-1, intercellular cell 
adhesion molecule (ICAM)-1, E-selectin, endothelial growth factor (EGF), and vascular 
endothelial growth factor (VEGF) were determined using a Biochip Array Technology 
analyzer (Evidence Investigator, Randox, Ireland). 
2.4 Activities of Lipoprotein-Associated Proteins and Enzymes  
CETP Activity. CETP activity was determined in serum samples according to the endogenous 
radiometric procedure of Lagrost et al. (15). Results were expressed as a percentage of 
3
H-
cholesteryl esters transferred from HDL3 to apoB-containing lipoproteins, per ml, per hour. 
Measurements were all carried out within the same assay. Within-run assay precision was 
4.9%. 
Lipoprotein-Associated Phospholipase A2 Activity. Lipoprotein-associated phospholipase A2 
(Lp-PLA2) activity was measured using the radiometric assay described by Blank et al.(16). 
Results were expressed as µmol per ml, per h. Measurements were all carried out within the 
















2.5 Lipoprotein Isolation 
Plasma lipoproteins were isolated from serum and plasma by a single step, isopycnic 
non-denaturing density gradient ultracentrifugation using a Beckman SW41 Ti rotor at 40,000 
rpm for 44 hours in a Beckman XL70 ultracentrifuge at 15°C by a slight modification of the 
method of Chapman et al. (17) as previously described (18). Briefly, plasma density was 
increased to 1.21 g/mL by adding dry solid KBr. A discontinuous density gradient was then 
constructed as follows: 2 mL of 1.24 g/mL NaCl/KBr solution, 3 mL plasma (d 1.21 g/mL), 2 
mL of 1.063 g/mL NaCl/KBr solution, 2.5 mL of 1.019 g/mL NaCl/KBr solution, and 2.5 mL 
of NaCl solution (d 1.006 g/mL). All density solutions contained sodium azide (0.01%), 
EDTA (0.01%), and gentamicin (0.005%), pH 7.4. After centrifugation, gradients were 
collected from the top of the tube in 12 fractions corresponding to VLDL (d <1.017 g/mL), 
IDL (d 1.018 to 1.019 g/mL), LDL1 (d 1.019 to 1.023 g/mL), LDL2 (d 1.023 to 1.0239 
g/mL), LDL3 (d 1.029 to 1.039 g/mL), LDL4 (d 1.039 to 1.050 g/mL), LDL5 (d 1.050 to 
1.063 g/mL), HDL2b (d 1.063 to 1.091 g/mL), HDL2a (d 1.091 to 1.110 g/mL), HDL3a (d 
1.110 to 1.133 g/mL), HDL3b (d 1.133 to 1.156 g/mL), and HDL3c (d 1.156 to 1.179 g/mL). 
Density limits were defined using a calibration curve of density versus volume derived from 
control gradients containing only salt solutions.  
All lipoprotein fractions were dialysed against phosphate-buffered saline (PBS; pH 
7.4) at 4°C in the dark and analyzed for their lipid and protein content. Recovery was 98% for 
cholesterol and between 90% and 95% for all other lipids. Comparison of lipoprotein mass 
profiles as a function of density, computed from chemical analyses of lipoprotein subfractions 
isolated from aliquots of the same plasma fractionated in separate tubes during the same 
ultracentrifugal run, revealed a high degree of reproducibility; indeed, mass profiles were 
















subfractions. Importantly, this density gradient procedure allows fractionation of HDL 
particle subspecies in a non-oxidised, native state (17, 19). 
2.6 Chemical Analysis of Llipoproteins 
Total protein (TP), TC, free cholesterol (FC), PL and TG contents of isolated HDL 
subfractions were determined using commercially available assays (Diasys, France). 
Cholesteryl ester (CE) was calculated by multiplying the difference between total and free 
cholesterol concentrations by 1.67. Total lipoprotein mass was calculated as the sum of TP, 
CE, FC, PL and TG. ApoA-I and apoA-II contents in HDL were quantitated by 
immunoturbidimetry (Diasys, France).  
2.7 Antioxidative Activity of HDL3c 
Antioxidative activity of serum-derived HDL3c subfraction (final concentration, 10 
mg total mass/dl) was assessed towards reference LDL (10 mg TC/dl) isolated from a single 
plasma sample obtained from a reference healthy normolipidemic donor. The sample was 
aliquoted, stored at -80°C under nitrogen and used for all the experiments. LDL was oxidized, 
alone or in the presence of individual HDL3c isolated from each of T2DWC (n=10), T2DPC 
(n=8) and control (n=11) subjects, by 2,2′-azobis-(2-amidinopropane) hydrochloride (AAPH), 
an azo-initiator of lipid peroxidation (1 mM) (11, 20, 21). The HDL3c subfraction was added 
to LDL directly before oxidation. Serum was used as a source of HDL for this assay to ensure 
intact paraoxonase 1 (PON1) activity, which is inhibited by EDTA (22). Accumulation of 
conjugated dienes was measured as the increment in absorbance at 234 nm. Absorbance 
kinetics was corrected for the absorbance of AAPH itself run in parallel as a blank. The 
kinetics of diene accumulation revealed two characteristic phases, the lag (initiation) and 
propagation phases. For each curve, the duration of each phase, average oxidation rates within 
















amount of dienes) were calculated. The coefficient of variation (CV) remained below 10% for 
all the parameters. 
2.8 HDL3c lipidomic analysis 
Ten PL and sphingolipid (SL) subclasses, specifically phosphatidylcholine (PC), 
sphingomyelin (SM), lysophosphatidylcholine (LPC), phosphatidylethanolamine (PE), 
phosphatidylinositol (PI), phosphatidylserine (PS), PC-based plasmalogen (PC-pl), ceramide 
(Cer), phosphatidic acid (PA) and phosphatidylglycerol (PG), comprising together >160 
individual lipid species were assayed by LC/MS/MS. The PL subclasses were divided into 
major (those whose content was >1% of total PL, i.e. PC, SM, LPC, PE and PI) and minor 
(those whose content was <1% of total PL, i.e.  PS, PC-pl, Cer, PA and PG). 
Extraction: The HDL3c subpopulation (30µg of enzymatically-quantified PLs) was 
extracted with 4ml of cold CHCl3/acidified CH3OH (5/2, v/v) containing 4µg of PC d9, 400ng 
of LPC 15:0, 100ng of PI 25:0, 80ng of PE 25:0, 80ng of PA 25:0, 40ng of PS 25:0, 20ng of 
PG 25:0 and 20ng of Cer 17:0. Lipid standards were purchased from Avanti Polar Lipids 
(Alabaster, AL, USA). A blank and a control samples were extracted in parallel with each 
batch to ensure for quality control; each sample was corrected for blank readings. K4EDTA 
(200mM) solution was added (1:5 v/v) and the mixture was vortexed for 1 min and 
centrifuged at 3600 g for 10 min at 4°C. The organic phase was transferred into 5ml 
chromacol glass tubes and dried under nitrogen. PLs were reconstituted into 150µl 
isopropanol/hexane/water (10/5/2, v/v), transferred into LC/MS amber vials with inserts and 
dried under nitrogen. Lipids were reconstituted in 40µl of isopropanol/hexane/water (10/5/2, 
v/v) and lipids measured by LC/MS/MS.  
LC/MS analysis: Ten PL and SL subclasses were quantified by LC-ESI/MS/MS using 
a QTrap 4000 mass spectrometer (AB Sciex, Framingham, MA, USA): Lipid species were 
















lipid class. PC, LPC and SM species were detected as product ions of m/z 184, PE, PS, PG 
and PA as neutral losses of respectively m/z 141, 185, 189 and 115, PI molecular species as 
product ions of m/z -241. N2 was used as a collision gas. PE, PS, PG, PI, PA and ceramide 
species were monitored for 18 ms, PC, LPC and SM species were monitored for 30 ms at a 
unit resolution (0.7 atomic mass unit at half peak height).  
Quantification: Lipids were quantified using calibration curves specific for the nine 
individual lipid classes and up to 12 fatty acid moieties. Twenty-three calibration curves were 
generated in non-diluted and 10-fold diluted matrices to correct for matrix-induced ion 
suppression effects. More abundant lipid species which displayed non-linear response in non-
diluted extracts were quantified from a 10- or 100-fold diluted sample. An in-house developed 
Excel Macro was used to compile the data from the three injections. 
Limits of detection (LOD) and limits of quantitation (LOQ) were assessed using at 
least two individual lipid species per each PL or SL subclass and equaled 0.5 nM for Cer, 0.25 
nM for LPC, 25 nM for LPE, between 50 and 200 nM for PA, between 60 and 250 pM for 
PC, between 5 and 10 nM for PE, 1 nM for PG, 10 nM for PI, between 1 and 2 nM for PS and 
250 pM for SM. 
Repeatability of lipidomic analysis was tested in nine quality control samples 
extracted on three different occasions. The average coefficient of variation (CV) for 
individual lipid species was 11.6%; importantly, 90% of all the species revealed CV below 
20%. Lipid species displaying CV greater than 20% were exclusively present in minor 
abundance close to LOD. 
2.9 Statistical Analysis 
Distributions of all variables were analysed for normality using the Shapiro Wilk test. 
Normally distributed variables are expressed as means  SD and non-Gaussian distributed 
















normally-distributed variables were analyzed using Student’s t-test. For non-Gaussian 
distributed variables, the non-parametric Mann-Whitney U-test was employed. When 
comparing more than two groups, variables were first normalized by log or reciprocal 
transformation and then differences were evaluated using Bonferroni’s post-hoc test. 
Differences in dichotomous variables were analyzed by Fisher’s exact test. Spearman’s 
correlation coefficients were calculated to evaluate relationships between variables. 
Differences were considered statistically significant at p<0.05.  
Power analysis using G*Power software (Dusseldorf University, Dusseldorf, 
Germany) was performed to estimate the sample size required to detect differences between 
groups in accordance with previous studies performed in patients with Metabolic Syndrome 
and T2D (11) (23). 
The statistical software employed was INFOSTAT (University of Córdoba, Argentina) 
and SPSS 17.0 (Chicago, Illinois, USA). 
Principal component analysis and heatmap generation were performed using R 



















3.1 Clinical Parameters, Lipoprotein Profile and Inflammatory Biomarkers 
 Age and sex distribution were similar across the three study groups (Table 1). As 
expected, both T2D groups exhibited increased BMI as well as elevated plasma TG, VLDL-
C, and reduced plasma HDL-C concentrations relative to controls, reflecting dyslipidemia of 
insulin-resistant states. Glucose and HbA1c concentrations were progressively increased from 
the control group to T2DWC and further to T2DPC groups (Table 1). By contrast, there was 
no significant difference in TC, LDL-C, apoB and apoA-I concentrations between the groups; 
non-HDL-C levels were only elevated in poorly-controlled patients. Noteworthy, CETP 
activity, which may induce HDL enrichment in TG and depletion in cholesteryl esters, was 
increased in T2DPC patients compared to control subjects. 
The presence of a chronic inflammatory state in poorly-controlled patients was 
evidenced by elevated plasma concentrations of hsCRP, ICAM-1, E-selectin, EGF and VEGF 
(Table 2). Furthermore, the novel vascular inflammatory biomarker, plasma Lp-PLA2 activity, 
was significantly increased in the T2DPC group. By contrast, only E-selectin levels and Lp-
PLA2 activity were elevated in well-controlled patients. Circulating concentrations of IL-6 
and VCAM-1 did not differ between the groups. Overall, diabetic patients featured classical 
atherogenic dyslipidemia of T2D in a coexistence with a chronic proinflammatory state which 
















3.2 Total Chemical Composition of HDL subfractions. 
All five HDL subpopulations isolated by density gradient ultracentrifugation from the 
both groups of diabetic patients were depleted in CE and enriched in TG (with the exception 
of T2DWC HDL3b and 3c) as compared to control subjects (Table 3). In parallel, FC was 
reduced in HDL2a and 3a particles from the both T2D groups relative to controls. 
Additionally, PL content was significantly increased in diabetic patients across the whole 
spectrum of HDL, except the buoyant HDL2b subpopulation, relative to controls. 
Noteworthy, HDL3c PL content was increased in the T2DPC compared to the other groups. 
Furthermore, the content of TP was specifically decreased in T2DPC HDL3c vs. controls. 
Finally, large, light HDL2b and HDL2a particles from the both T2D groups were 
characterised by reduced apoA-I/apoA-II ratio, consistent with altered properties of HDL 
surface. 
Interestingly, TG and apolipoprotein content of HDL were altered in association with 
plasma CETP activity. This observation is consistent with the role of CETP as a key factor 
accounting for the altered lipid core composition of HDL in T2D (24). Indeed, CETP activity 
was positively correlated with HDL3b content of TG (r=0.45, p<0.05) and negatively 
correlated with the apoA-I/apoA-II ratio in HDL2b, HDL3b and HDL3c (r=-0.58, p<0.05; r=-
0.56, p<0.05; r=-0.69, p<0.01; respectively).  
In addition, CETP activity was directly correlated with plasma HbA1c levels (r=0.44, 
p<0.05). As a consequence, several modifications in the chemical composition of HDL 
subpopulations were correlated with HbA1c. Importantly, HbA1c was positively correlated 
with TG content of small, dense HDL3b and HDL3c subfractions (r=0.48, p<0.01; r=0.40, 
p<0.05; respectively), while negatively correlated with CE content of HDL3b (r=-0.45, 
















appeared to specifically affect chemical composition of small, dense HDL particles in the 
















3.3 Role of glycemic control for HDL characteristics 
Our earlier studies revealed that altered lipid core composition can contribute to the 
attenuation of antioxidative activity of HDL3c particles in T2D (11). Therefore, the capacity 
of HDL3c to protect LDL from oxidative stress was analysed in the present study. To 
characterise LDL oxidation kinetics, two characteristic oxidation phases, the initial lag phase 
and the ensuing propagation phase, as well as the maximal amount of conjugated dienes 
formed were analysed. Interestingly, the maximal diene concentration observed in LDL 
incubated with HDL3c particles from the T2DPC group was significantly increased as 
compared to that measured in the presence of control HDL3c, evidencing diminished capacity 
of HDL3c to prevent LDL oxidation in vitro (Figure 1). By contrast, no difference in other 


















3.4 Phosphosphingolipid species of HDL3c 
Using a lipidomic approach, ten PL and SL subclasses (PC, LPC, SM, PE, PI, PS, PC, 
Cer, PG and PA) were quantitatively assayed in small, dense HDL3c by LC/MS/MS and 
compared between the study groups (Figure 2). Among the major PL species (defined as those 
present at >1 wt% of total PL), PC and PI were elevated in T2DPC HDL3c as compared to its 
counterpart from control subjects. Interestingly, HDL3c contents of PC and PI were directly 
correlated with HbA1c (r=0.40, p=0.05; r=0.55, p=0.004, respectively). 
Regarding minor lipid classes, Cer content was increased in T2DPC HDL3c in 
comparison with its counterparts from T2DWC and control subjects. Furthermore, HDL3c 
Cer content tended to be associated with Hb 1c (r=0.39, p=0.06). Finally, PC and Cer 
contents of HDL3c were positively associated with the maximal diene concentration 
measured during LDL incubation with HDL3c (r=0.40, p=0.048; r=0.42, p=0.040, 
respectively). Between-group distributions of individual lipid species were largely consistent 
with those observed for the lipid subclasses (Suppl. Figure 1). Indeed, numerous species of 
PC, PI and Cer were significantly elevated in the T2DPC group relative to controls. 
Lipidomic data projected onto the plane space depicting maximal inertia (total 
variance) of the dataset were utilized during principal component analysis. The first, second, 
third and fourth principal components explained 53% of the data variance, which allowed 
certain distinguishing between diabetic and control subjects (Suppl. Figure 2). Lipidomic 
alterations associated with T2D were visualized as a heat map presenting ratios of each lipid 
concentration measured in individual T2DWC or T2DPC subjects to the corresponding mean 
concentrations measured in control subjects, thereby revealing a large number of altered lipid 
species in the T2DWC and T2DPC groups (Suppl. Figure 3). A dendrogram with a leaf 
structure constructed using these data revealed two clusters of subjects. Each of the clusters 
















the two groups were qualitatively similar, although those found in T2DPC were more 
















3.5 Fatty Acid Composition of Phospho- and Sphingolipids in HDL3c  
 Phospho- and sphingolipid species classified according to the level of unsaturation of 
their esterified fatty acid moieties were also evaluated in HDL3c. Importantly, HDL content 
of highly oxidable polyunsaturated fatty acids (PUFA) residues was significantly elevated in 
T2DPC patients in the PC subclass which predominates in plasma HDL, accounting for 74% 
to 80% of the total phospho- and sphingolipidome (7). In addition, the content of PUFAs in 
less abundant PI, PG and Cer subclasses was also increased in the T2DPC group as compared 
to controls (Table 4). By contrast, there was no significant difference between the groups in 
the HDL3c content of saturated fatty acid (SFA) and monounsaturated fatty acid (MUFA) in 
the PC subclass (data not shown). HDL3c SFAs were only elevated in low-abundant PE, PI 
and Cer subclasses, whereas MUFAs were increased in PE, PI, PG and Cer (Table 4).  
Finally, PC-PUFA and Cer-PUFA contents in HDL3c were directly correlated with 
HbA1c (r=0.43, p=0.034; r=0.51, p=0.01, respectively) and with the maximal diene 



















 Patients with T2D display a three-fold increase in CV mortality and a two-fold 
increase in overall mortality compared to age-matched patients without diabetes (25). 
Although T2D has been well established to lead to modifications in HDL particles, the 
underpinnings of this phenomenon remain obscure. Patients with T2D typically present 
dyslipemia characterized by high TG and low HDL-C levels. However, such patients also 
display qualitative HDL alterations which are associated with the increased risk of CVD. In 
the present study we show that several molecular characteristics of small, dense HDL 
particles were altered in parallel to HbA1c levels in patients with T2D. As a consequence, 
HDL3c particles from T2D patients featuring poor glycemic control not only showed an 
altered chemical composition, but also displayed reduced capacity to prevent LDL oxidation.  
Antioxidative capacity of HDL3c was impaired in the T2DPC group. According to the 
oxidative hypothesis of atherosclerosis, LDL can be retained in the arterial wall and 
oxidatively modified. By contrast, HDL can protect LDL from oxidative stress, potentially 
contributing to the prevention of atherosclerosis. Removal of oxidized lipids from LDL 
represents the first step of HDL-mediated protection from oxidative damage. Inactivation of 
oxidized lipids associated with HDL particles represents the second step in this antioxidative 
pathway. Depending on their structure, oxidized lipids can be reduced by apoA-I and other 
redox-active HDL components (5). As expected, T2DPC patients presented HDL particles 
which were TG-enriched and CE-depleted. This is a classic compositional alteration found in 
insulin-resistant states, which is primarily linked to enhanced CETP activity, a finding 
confirmed in the present study. Notably, replacement of CE by TG in the HDL lipid core have 
been reported to result in a reduced penetration of the central and C-terminal regions of apoA-
I into the lipid phase (26), a structural alteration which may contribute to the functional 
















that increased CETP activity was associated with enrichment in TG and loss of ApoA-I from 
small, dense HDL particles, as the former was inversely correlated with the ApoA-I/ApoA-II 
ratio in HDL3b and 3c. 
Interestingly, our previous work showed that composition of small, dense HDL3 
particles was markedly affected in T2D patients and that these modifications were associated 
with both glycaemia and hypertriglyceridemia (11). In the present work, correlational analysis 
revealed that several compositional alterations in small, dense HDL3 were only associated 
with HbA1c levels. Moreover, HDL3c particles from T2DPC were the only HDL subfraction 
that was enriched in TG and PL, depleted in CE and TP, and exhibited defective functionality, 
suggesting that HDL3c represents the preferential target for poor glycemic control across the 
HDL particle profile. Potential clinical implications of this observation are highlighted by the 
fact that small, dense HDL3 exert potent atheroprotective activities and that reduced plasma 
levels of HDL3 can enhance cardiovascular risk. Indeed, the VA-HIT trial reported that 
plasma levels of HDL3-C were a powerful predictor of cardiovascular risk in insulin-resistant 
subjects, even more strong than total HDL-C (28). In addition, these studies found that HDL3-
C, but not HDL2-C, at baseline and as a percentage change with fibrates therapy was 
significantly related to the incidence of coronary heart disease (28). Moreover, a recent work 
from our laboratory showed that small, dense HDL3c displayed more potent capacity to efflux 
cellular cholesterol from lipid-loaded human macrophages as compared to other HDL 
subpopulations (9). These data suggest that alterations in small, dense HDL particles can play 
a role in the development of atherosclerosis in T2D. 
Additional alterations observed in the lipidomic composition of small, dense HDL3c 
in T2DPC were the enrichment in PC, PI and Cer. Of note, PC represents the key structural 
PL of cell membranes and lipoproteins, accounting for 33-45 wt% of total lipid in HDL (5). In 
















susceptibility of HDL and lower its capacity to prevent oxidation of LDL particles. Our 
previous studies confirmed deleterious effects of PC enrichment on antioxidative activity of 
HDL using in vitro experiments (29). Moreover, specific increase in PUFA-enriched PC has 
previously been reported to be associated with insulin levels (30). In agreement with this 
observation, HDL3c from T2DPC displayed increased content of PC-PUFA accompanied by 
impaired antioxidative capacity in our study, suggesting that HDL content of PC-PUFA can 
serve as a negative biomarker of antiatherogenic functionality of HDL. Interestingly, the 
lipidomic analysis revealed that alterations observed in T2DPC and T2DWC groups were 
qualitatively similar, although those found in T2DPC were more pronounced, consistent with 
the role of the glycemic control. 
Among the major PL species, PI is a negatively-charged phospholipid regulating 
intracellular signalling cascades that was previously reported to be enriched in small, dense 
HDL3 (7). Interestingly, we observed that HDL3c content of PI-PUFA was also increased in 
T2DPC, potentially further contributing to the overall reduction in the antioxidative capacity. 
In addition, HDL3c content of Cer, a proinflammatory lipid implicated in the development of 
skeletal muscle insulin resistance and macrophage inflammation (30), directly correlated with 
impaired antioxidative capacity. Consistent with these data, previous reports have shown Cer 
levels to be associated with the development of T2D and prediabetes (31-33). Moreover, Cer 
has been demonstrated to be detrimental to pancreatic beta cells (34-36) and may therefore 
play an important role in the pathogenesis of T2D. 
Similar phospholipidomic-based studies carried out in diabetic patients also reported 
alterations in the HDL PL content (30). Thus, Stahlman and colleagues observed that 
dyslipidemia predominated relative to hyperglycemia for the occurrence of alterations in the 
HDL lipidome, in contrast to what we describe for the small, dense HDL3c particles in the 
















al. studied total HDL (30), while we focused on the small, dense HDL3c subfraction, which 
appears more likely to be affected by the glycemic imbalance. The contribution of HDL3c to 
total HDL lipid mass does not exceed 10%, rendering undetectable alterations in the HDL3c 
lipidome upon analysing total HDL. In addition, Stahlman et al. evaluated three groups of 
women, a control one together with two groups featuring T2D and insulin resistance. 
Importantly, the both T2D groups displayed similar HbA1c levels in this study (30), 
complicating evaluation of the impact of the glycemic status on the HDL lipidome.  
In summary, the present study for the first time identifies PL subclasses altered in 
small, dense HDL3 from patients with T2D in association with impaired HDL functionality. 
The study is not free of limitations, the major of which involves the small number of included 
subjects. Importantly however, essentially treatment-naïve patients and controls recruited in 
order to avoid a drug-treatment bias renders this cohort unique for modern T2D research. 
The prevalence of diabetes worldwide is increasing; by 2030, 439 million people are 
expected to be living with T2D (37). This number highlights the need of novel therapeutic 
strategies for this disease. Lipid parameters presently evaluated in T2D, including TG, TC, 
HDL-C and LDL-C, provide only a narrow snapshot of the dynamic processes of lipid 
metabolism. Functional evaluation of HDL particles combined with lipidomic approaches 
bear a potential to improve current CV risk prediction tools. It is important in this regard that 
the present study not only documents the presence of profound molecular alterations in small, 
dense HDL in poorly-controlled T2D, but equally introduces the notion of the glycemic status 
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Figure 1: Influence of small, dense HDL3c (10 mg total mass/dl) on AAPH-induced 
oxidation of reference LDL in T2DPC patients (n=8), T2DWC patients (n=10), and control 
subjects (n=11). Reference LDL (10 mg TC/dl) was incubated at 37°C in PBS in the presence 
of AAPH (1 mmol/l). Data are shown as % of values measured in reference LDL incubated 
without added HDL. For each curve oxidation rates of initiation phase and propagation phase, 
and the amount of dienes formed at the end of propagation phase (maximal amount of dienes 
concentration) of LDL oxidation are shown. T2DPC, poorly-controlled Type 2 diabetes; 
T2DWC, well-controlled Type 2 diabetes. p-value obtained by ANCOVA. 
†
, significant 
difference between T2DPC vs. control subjects. 
 
Figure 2: Phospho- and sphingolipidome of small, dense HDL3c in T2DPC (n=8), T2DWC 
(n=10) and control subjects (n=11). A, major lipid subclasses: PC, phosphatidylcholine; SM 
sphingomyelin; LPC, lysophosphatidylcholine; PE, phosphatidylethanolamine and PI, 
phosphatidylinositol; and B, minor lipid subclasses (logarithmic scale): PG, 
phosphatidylglycerol; PA, phosphatidic acid; PS, phosphatidylserine; Cer, ceramide. T2DPC, 
poorly-controlled Type 2 diabetes; T2DWC, well-controlled Type 2 diabetes. 
†
p<0.01, 
significant difference between T2DPC vs. control subjects. 
ɸ
p<0.01, significant difference 
between T2DPC vs. T2DWC and control subjects.  
 
Supplementary Figure 1: Individual phospho- and sphingolipid species in small, dense 
HDL3c from T2DPC (n=8), T2DWC (n=10) and control subjects (n=11). T2DPC, poorly-
controlled Type 2 diabetes; T2DWC, well-controlled Type 2 diabetes. 
 
Supplementary Figure 2: Principal component analysis of HDL3c lipidomic data from 
T2DPC (n=8), T2DWC (n=10) and control subjects (n=11). For simplicity, two-dimensional 
covariance matrix is shown for the principal components 1 and 3. T2DPC, poorly-controlled 

















Supplementary Figure 3: Heat map of the ratios of the content of individual lipid species in 
HDL3c from T2DPC (n=8) and T2DWC (n=10) patients relative to control subjects (n=11). 
Rows indicate T2DPC and T2DWC patients; columns represent individual lipid siècles 
grouped into their classes (LPE, PE, PS, PG, PA, Cer, PI, LPC, PC, SM). A dendrogram was 
constructed using the weights calculated by heatmap.2 function from gplots package; the 
branches of the dendrogram were reordered according to the weights. At each node, the 
branches are ordered in the order of increasing weight; the weight of a branch is defined by 






































Sex (Females/Males) 7/1 7/3 8/3 NS 
Body Mass Index (kg/m
2
) 29.51.4 31.95.7 24.23.4* 0.01 
Glucose (mg/dl) 157 (113-225) 133 (89-139) 78 (67-87)* 0.001 
HbA1c (%) 9.5 (8.9-10.5) 6.2 (5.8-6.4) 5.6 (3.9-5.7)
ɸ
 0.001 
TG (mg/dl) 234 (185-257) 195 (176-221) 73 (58-80)* 0.001 
TC (mg/dl) 21835 20244 19922 NS 
VLDL-C (mg/dl) 47 (26-48) 37 (22-44) 19 (15-21)* 0.001 
LDL-C (mg/dl) 13733 12043 11521 NS 
HDL-C (mg/dl) 378 388 6510* 0.001 
Non-HDL-C (mg/dl) 18233 16344 13421
†
 0.01 
ApoB (mg/dl) 135 (107-173) 138 (66-173) 86 (69-125) NS 
ApoA-I (mg/dl) 134 (120-182) 139 (108-153) 150 (140-254) NS 




T2DPC, poorly controlled type 2 diabetes; T2DWC, well controlled type 2 diabetes; HbA1c, 
glycated haemoglobin; TC, total cholesterol; TG, triglycerides; LDL-C, low density 
lipoprotein-cholesterol; HDL-C, high density lipoprotein-cholesterol; VLDL-C, very low-
density lipoprotein-cholesterol; apo, apolipoprotein. Data are expressed as mean  S.D. or 
median (interquartile range), depending on data distribution. Shown p-values were obtained 
















and T2DWC vs. control subjects. 
†
, significant difference between T2DPC vs. control 
subjects. 
ɸ









































IL-6 (pg/ml) 1.6 (1.4-3.3) 1.7 (1.4-2.3) 0.9 (0.7-1.1) NS 
VCAM-1 (ng/ml) 691  90 639  84 671  67 NS 
ICAM-1 (ng/ml) 315 (304-330) 262 (238-307) 219 (207-225)
†
 0.01 
E-Selectin (ng/ml) 22  6 22  6 13  5* 0.05 
EGF (pg/ml) 41 (40-42) 23 (10-50) 5 (4-16)
†
 0.05 
VEGF (pg/ml) 64  30 26  18 47  29
Δ
 0.05 
Lp-PLA2 Activity (µmol/ml.h) 7.3 1.5 7.3 2.2 5.3 1.1* 0.01 
 
T2DPC, poorly controlled type 2 diabetes; T2DWC, well controlled type 2 diabetes; hsCRP, 
high sensitivity C reactive protein; IL, interleuquin; VCAM, vascular cell adhesion molecule; 
ICAM, intercellular cell adhesion molecule; E-selectin, endothelial-selectin; EGF, endothelial 
growth factor; VEGF, vascular endothelial growth factor. Data are expressed as mean  S.D. 
or median (interquartile range), depending on data distribution. Shown p corresponds to that 
obtained from parametric or non-parametric ANOVA tests. *, significant difference between 
T2DPC and T2DWC vs. control subjects. 
†
, significant difference between T2DPC vs. control 
subjects. 
Δ


















TABLE 3: Total Mass and Total Lipid and Protein Composition of HDL 
Subpopulations from T2DPC (n=8), T2DWC (n=10) and Control Subjects (n=11) 
 
 
 Group HDL2b HDL2a HDL3a HDL3b HDL3c 
CE (wt %) T2DPC 203 182 182 172 152 
 T2DWC 213 193 182 173 153 
 Control 264* 242* 232* 213* 183* 
FC (wt %) T2DPC 3.10.5 2.50.2 2.00.1 1.40.4 1.20.4 
 T2DWC 3.40.6 2.50.2 1.90.3 1.40.6 1.00.6 
 Control 4.01.4 3.20.3* 2.40.3* 1.80.8 1.60.9 
TG (wt %) T2DPC 94 61 62 84 85 
 T2DWC 94 51 51 64 53 





PL (wt %) T2DPC 357 375 355 305 256 
 T2DWC 364 363 343 294 236 
 Control 354 324* 303* 263* 214
ɸ
 
Total protein (wt %) T2DPC 324 364 404 455 517 
 T2DWC 315 374 414 476 559 
 Control 312 383 422 482 564
†
 
ApoA-I/apoA-II T2DPC 3.80.8 2.60.3 2.70.3 3.71.1 5.60.7 
 T2DWC 3.31.2 2.60.3 2.70.3 3.91.0 5.70.8 

















HDL, high density lipoprotein; T2DPC, poorly controlled type 2 diabetes; T2DWC, well 
controlled type 2 diabetes; CE, cholesteryl esters; FC, free cholesterol; TG, triglycerides; PL, 
phospholipids; TP, total protein; apo, apolipoprotein. Data are expressed as mean  S.D. * 
p<0.05, significant difference between T2DPC and T2DWC vs. control subjects. † p<0.05, 
significant difference between T2DPC vs. control subjects, 
ɸ
 p<0.05, significant difference 

















TABLE 4. Significant different phospho- and sphingolipid species in HDL3c classified 
according to the level of unsaturation of esterified fatty acid moieties in T2DPC, 

























, wt%) 17.2 (10.7-100.2) 13.0 (11.1-21.3) 8.6 (6.6-10.3)
†
 0.05 





, wt%) 10.4 (10.1-10.7) 2.0 (1.7-3.1) 2.0 (1.5-2.5)
ɸ
 0.0001 
PI-PUFA (wt%) 0.740.18 0.550.19 0.470.17
†
  0.05 










, wt%) 4.01.5 2.61.5 1.81.5
†
 0.01 














T2DPC, poorly-controlled Type 2 diabetes; T2DWC, well-controlled Type 2 diabetes; SFA, 
saturated fatty acid; MUFA, monounsaturated fatty acid; PUFA, polyinsaturated fatty acid; 
PC, phosphatidylcholine; PE, phosphatidylethanolamine; PI, phosphatidylinositol; PG, 
phosphatidylglycerol; Cer, ceramide; wt%, weight % of total HDL3c mass. Data are 
expressed as mean  S.D. or median (interquartile range), depending on data distribution. p 
value obtained by ANCOVA. Only PL fatty acid classes that revealed significant between-
group differences are included in the table.†, significant difference between T2DPC vs. 
control subjects, ɸ , significant difference between T2DPC vs. T2DWC and control subjects. 
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Fig. 1 
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